Reactivating P53 to treat osteosarcoma: A tetrahedral framework nucleic acids-based approach

Osteosarcoma is a prevalent malignant tumor among adolescents, and the current five-year survival rate of osteosarcoma remains at 70 %, which has not improved in the last three decades. Therefore, there is an urgent need for drugs that can improve the prognosis of osteosarcoma patients. APR-246, also known as Eprenetapopt, is an activator of mutant P53. It has a good effect on promoting apoptosis of osteosarcoma cells, tetrahedral framework nucleic acids (tFNAs) are a small molecule drug delivery system with good biosafety, in order to improve the anti-osteosarcoma efficiency of APR-246, in the present study, a novel nanoparticle T-APR-246 was successfully synthesized using tFNAs to carry APR-246. In vivo and in vitro experiments showed that T-APR-246 more efficiently promoted osteosarcoma cell apoptosis and inhibited osteosarcoma cell proliferation and metastasis than APR-246. Our findings provide new research insights into the treatment of osteosarcoma.